Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
Company profile
Ticker
COEP
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bull Horn Holdings Corp.
SEC CIK
Corporate docs
Subsidiaries
Coeptis Therapeutics, Inc. • Coeptis Pharmaceuticals, Inc. • Coeptis Pharmaceuticals LLC ...
COEP stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
26 Mar 24
424B3
Prospectus supplement
26 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
10-K/A
2022 FY
Annual report (amended)
25 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
25 Mar 24
424B3
Prospectus supplement
5 Feb 24
424B3
Prospectus supplement
5 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm | 1.41 mm |
Cash burn (monthly) | 611.10 k | 496.62 k | 2.61 mm | 1.87 mm | 652.79 k | 532.76 k |
Cash used (since last report) | 3.66 mm | 2.97 mm | 15.63 mm | 11.17 mm | 3.91 mm | 3.19 mm |
Cash remaining | -2.25 mm | -1.56 mm | -14.22 mm | -9.76 mm | -2.50 mm | -1.78 mm |
Runway (months of cash) | -3.7 | -3.1 | -5.4 | -5.2 | -3.8 | -3.3 |
Institutional ownership, Q3 2023
32.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 4 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.69 bn |
Total shares | 11.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bull Horn Holdings Sponsor | 4.88 mm | $0.00 |
Armistice Capital | 2.21 mm | $2.57 bn |
Lena Pharma | 1.43 mm | $0.00 |
Lisa Pharma | 1.43 mm | $0.00 |
Creative Planning | 645.10 k | $748.32 mm |
Geode Capital Management | 124.71 k | $144.69 mm |
Vanguard | 89.62 k | $103.96 mm |
Cambridge Investment Research Advisors | 66.15 k | $77.00 k |
Ionic Capital Management | 45.00 k | $52.20 mm |
Shaolin Capital Management | 45.00 k | $52.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Tara DeSilva | Common Stock | Buy | Acquire P | No | No | 0.58 | 1,800 | 1.04 k | 32,266 |
12 Jan 24 | Tara DeSilva | Common Stock | Buy | Acquire P | No | No | 0.56 | 466 | 260.96 | 30,466 |
10 Jan 24 | Brian Cogley | Common Stock | Buy | Acquire P | No | No | 0 | 5,000 | 0.00 | 30,000 |
8 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.66 | 14,004 | 9.24 k | 2,782,615 |
8 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.67 | 6,000 | 4.02 k | 2,768,611 |
5 Jan 24 | Christopher P. Cochran | Common Stock | Buy | Acquire P | No | No | 0 | 7,000 | 0.00 | 37,000 |
5 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.69 | 5,050 | 3.48 k | 2,762,611 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
26 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
14 Mar 24
Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK
26 Feb 24
12 Health Care Stocks Moving In Monday's After-Market Session
12 Feb 24
12 Health Care Stocks Moving In Thursday's After-Market Session
8 Feb 24
Press releases
Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems
21 Feb 24
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
7 Feb 24
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
4 Jan 24